Antibody-based targeting of BCMA in multiple myeloma

Lancet Oncol. 2020 Feb;21(2):186-187. doi: 10.1016/S1470-2045(19)30819-8.

Authors

Gareth J Morgan¹, Louis Williams²

Affiliations

¹ NYU Langone Health, New York, NY 10016, USA. Electronic address: gareth.morgan@NYULangone.org.
² NYU Langone Health, New York, NY 10016, USA.

PMID: 32007191
DOI: 10.1016/S1470-2045(19)30819-8

No abstract available

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
B-Cell Maturation Antigen / antagonists & inhibitors*
B-Cell Maturation Antigen / immunology
Clinical Trials as Topic
Humans
Molecular Targeted Therapy
Multiple Myeloma / drug therapy*
Multiple Myeloma / immunology
Multiple Myeloma / mortality
Multiple Myeloma / pathology
Progression-Free Survival

Substances

Antineoplastic Agents, Immunological
B-Cell Maturation Antigen
TNFRSF17 protein, human